- Home
Clinical trials - page 11

Search for a clinical trial
Filter
Filter
Geographical location
Type of cancer
Refine your search
Age
Phase
Search for a clinical trial
183 result(s)
- Breast cancerParisTRANS ROSALEEA BIOMARKER-DIRECTED, TRANSLATIONAL STUDY OF HIGH-THROUGHPUT MOLECULAR PROFILING OF HR+/HER2- METASTATIC BREAST CANCER TREATED WITH ENDOCRINE THERAPY AND RIBOCICLIB.
HELENE SALAUN
- SarcomasParisTRUSTBintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma (TRUST)
CLEMENT BONNET
- Paris, Saint-CloudTUMOSPEC (ONCO04) - ParisInvestigation of Tumour Spectrum, Penetrance and Clinical Utility of Germline Mutations in New Breast and Ovarian Cancer Susceptibility Genes.
DOMINIQUE STOPPA-LYONNET
- ParisTUMOSSComparative Evaluation of Care Strategies on Dressing Change-induced Bleeding in Patients With Bleeding Malignant Wounds (TUMOSS)
- Lung cancerParisTelimet-01: M18-868A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin;(ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype,;Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
NICOLAS GIRARD
- Breast cancerParis, Saint-CloudTreat ctDNAElacestrant for Treating ER+/·HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (TREAT ctDNA)
FRANCOIS-CLEMENT BIDARD, ETIENNE BRAIN
- Cancers gynécologiquesParisVS-6766-301 (RAMP 301)A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus;InvestigatorÀs Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC).
MANUEL RODRIGUES
- Saint-CloudYO39523A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Childhood and adolescent cancersPariseSMARTEuropean Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors.
ISABELLE AERTS GAJDOS
- Childhood and adolescent cancersParisiMATRIX-Alectinib (GO42286)A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available.
FRANCOIS DOZ